Chronic	chronic	O	O
carbamazepine	carbamazepine	O	O
treatment	treatment	O	O
in	in	O	O
the	the	O	O
rat	rat	O	O
:	:	O	O
efficacy	efficacy	O	O
,	,	O	O
toxicity	toxicity	O	O
,	,	O	O
and	and	O	O
effect	effect	O	O
on	on	O	O
plasma	plasma	O	O
and	and	O	O
tissue	tissue	O	O
folate	folate	O	O
concentrations	concentrations	O	O
.	.	O	O

Folate	folate	O	O
depletion	depletion	O	O
has	has	O	O
often	often	O	O
been	been	O	O
a	a	O	O
problem	problem	O	O
in	in	O	O
chronic	chronic	O	O
antiepileptic	antiepileptic	B_chemicals	O
drug	drug	S_chemicals	O
(	(	O	O
AED	aed	O	O
)	)	O	O
therapy	therapy	O	O
.	.	O	O

Carbamazepine	carbamazepine	O	O
(	(	O	O
CBZ	cbz	O	O
)	)	O	O
,	,	O	O
a	a	O	O
commonly	commonly	O	O
used	used	O	O
AED	aed	O	O
,	,	O	O
has	has	O	O
been	been	O	O
implicated	implicated	O	O
in	in	O	O
some	some	O	O
clinical	clinical	O	O
studies	studies	O	O
.	.	O	O

A	a	O	O
rat	rat	O	O
model	model	O	O
was	was	O	O
developed	developed	O	O
to	to	O	O
examine	examine	O	O
the	the	O	O
effects	effects	O	O
of	of	O	O
chronic	chronic	O	O
CBZ	cbz	O	O
treatment	treatment	O	O
on	on	O	O
folate	folate	O	O
concentrations	concentrations	O	O
in	in	O	O
the	the	O	O
rat	rat	O	O
.	.	O	O

In	in	O	O
the	the	O	O
course	course	O	O
of	of	O	O
developing	developing	O	O
this	this	O	O
model	model	O	O
,	,	O	O
a	a	O	O
common	common	O	O
vehicle	vehicle	O	O
,	,	O	O
propylene	propylene	B_chemicals	O
glycol	glycol	I_chemicals	O
,	,	O	O
by	by	O	O
itself	itself	O	O
in	in	O	O
high	high	O	O
doses	doses	O	O
,	,	O	O
was	was	O	O
found	found	O	O
to	to	O	O
exhibit	exhibit	O	O
protective	protective	O	O
properties	properties	O	O
against	against	O	O
induced	induced	O	O
seizures	seizures	O	S_disease
and	and	O	O
inhibited	inhibited	O	O
weight	weight	O	B_disease
gain	gain	O	I_disease
.	.	O	O

Seizures	seizures	O	S_disease
induced	induced	O	O
by	by	O	O
hexafluorodiethyl	hexafluorodiethyl	O	O
ether	ether	S_chemicals	O
(	(	O	O
HFDE	hfde	O	O
)	)	O	O
were	were	O	O
also	also	O	O
found	found	O	O
to	to	O	O
be	be	O	O
a	a	O	O
more	more	O	O
sensitive	sensitive	O	O
measure	measure	O	O
of	of	O	O
protection	protection	O	O
by	by	O	O
CBZ	cbz	O	O
than	than	O	O
seizures	seizures	O	S_disease
induced	induced	O	O
by	by	O	O
maximal	maximal	O	O
electroshock	electroshock	O	O
(	(	O	O
MES	mes	O	O
)	)	O	O
.	.	O	O

Oral	oral	O	O
administration	administration	O	O
of	of	O	O
CBZ	cbz	O	O
as	as	O	O
an	an	O	O
aqueous	aqueous	O	O
suspension	suspension	S_chemicals	O
every	every	O	O
8	8	O	O
h	h	O	O
at	at	O	O
a	a	O	O
dose	dose	O	O
of	of	O	O
250	250	O	O
mg/kg	mg/kg	O	O
was	was	O	O
continuously	continuously	O	O
protective	protective	O	O
against	against	O	O
HFDE-induced	hfde-induced	O	O
seizures	seizures	O	S_disease
and	and	O	O
was	was	O	O
minimally	minimally	O	O
toxic	toxic	O	O
as	as	O	O
measured	measured	O	O
by	by	O	O
weight	weight	O	B_disease
gain	gain	O	I_disease
over	over	O	O
8	8	O	O
weeks	weeks	O	O
of	of	O	O
treatment	treatment	O	O
.	.	O	O

The	the	O	O
CBZ	cbz	O	O
levels	levels	O	O
measured	measured	O	O
in	in	O	O
plasma	plasma	O	O
and	and	O	O
brain	brain	O	O
of	of	O	O
these	these	O	O
animals	animals	O	O
,	,	O	O
however	however	O	O
,	,	O	O
were	were	O	O
below	below	O	O
those	those	O	O
normally	normally	O	O
considered	considered	O	O
protective	protective	O	O
.	.	O	O

This	this	O	O
treatment	treatment	O	O
with	with	O	O
CBZ	cbz	O	O
had	had	O	O
no	no	O	O
apparent	apparent	O	O
adverse	adverse	O	O
effect	effect	O	O
on	on	O	O
folate	folate	O	O
concentrations	concentrations	O	O
in	in	O	O
the	the	O	O
rat	rat	O	O
,	,	O	O
and	and	O	O
,	,	O	O
indeed	indeed	O	O
,	,	O	O
the	the	O	O
folate	folate	O	O
concentration	concentration	O	O
increased	increased	O	O
in	in	O	O
liver	liver	O	O
after	after	O	O
6	6	O	O
weeks	weeks	O	O
of	of	O	O
treatment	treatment	O	O
and	and	O	O
in	in	O	O
plasma	plasma	O	O
at	at	O	O
8	8	O	O
weeks	weeks	O	O
of	of	O	O
treatment	treatment	O	O
.	.	O	O

